Maravai LifeSciences (MRVI) to Release Earnings on Monday

Key Points

• Maravai LifeSciences is set to release its Q2 2025 earnings on August 11, with expectations of a loss of ($0.06) per share and revenue of $47.46 million.
• The company reported a loss of ($0.08) per share in the previous quarter, which was below the consensus estimate, despite revenue exceeding expectations at $46.85 million.
• Shares of Maravai LifeSciences are currently priced at $2.22, with a market cap of $565.35 million and a consensus rating of "Hold" among analysts.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) is expected to be posting its Q2 2025 quarterly earnings results after the market closes on Monday, August 11th. Analysts expect Maravai LifeSciences to post earnings of ($0.06) per share and revenue of $47.46 million for the quarter. Maravai LifeSciences has set its FY 2025 guidance at EPS.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The firm had revenue of $46.85 million for the quarter, compared to analyst estimates of $44.01 million. Maravai LifeSciences had a negative return on equity of 12.91% and a negative net margin of 67.14%. The firm's revenue for the quarter was down 26.9% compared to the same quarter last year. On average, analysts expect Maravai LifeSciences to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Maravai LifeSciences Stock Performance

Shares of Maravai LifeSciences stock opened at $2.22 on Monday. The company has a debt-to-equity ratio of 0.60, a current ratio of 5.96 and a quick ratio of 5.17. The firm has a market cap of $565.35 million, a P/E ratio of -1.95 and a beta of 0.28. The firm has a 50 day simple moving average of $2.40 and a 200 day simple moving average of $2.77. Maravai LifeSciences has a fifty-two week low of $1.66 and a fifty-two week high of $9.95.

Hedge Funds Weigh In On Maravai LifeSciences

A hedge fund recently raised its stake in Maravai LifeSciences stock. Jane Street Group LLC raised its holdings in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report) by 1,463.1% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 380,403 shares of the company's stock after acquiring an additional 356,067 shares during the quarter. Jane Street Group LLC owned about 0.15% of Maravai LifeSciences worth $841,000 as of its most recent SEC filing. 50.25% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Robert W. Baird lowered their price target on shares of Maravai LifeSciences from $3.00 to $2.00 and set a "neutral" rating for the company in a report on Tuesday, May 13th. Craig Hallum lowered their price target on shares of Maravai LifeSciences from $12.00 to $10.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $6.64.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.